Codexis Inc (CDXS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Codexis Inc stock (CDXS) is currently trading at $1.67. Codexis Inc PS ratio (Price-to-Sales) is 2.07. Analyst consensus price target for CDXS is $6.58. WallStSmart rates CDXS as Underperform.
- CDXS PE ratio analysis and historical PE chart
- CDXS PS ratio (Price-to-Sales) history and trend
- CDXS intrinsic value — DCF, Graham Number, EPV models
- CDXS stock price prediction 2025 2026 2027 2028 2029 2030
- CDXS fair value vs current price
- CDXS insider transactions and insider buying
- Is CDXS undervalued or overvalued?
- Codexis Inc financial analysis — revenue, earnings, cash flow
- CDXS Piotroski F-Score and Altman Z-Score
- CDXS analyst price target and Smart Rating
Codexis Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Codexis Inc (CDXS) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, institutional own.. Concerns around market cap and peg ratio. Mixed signals suggest waiting for clearer direction before acting.
Codexis Inc (CDXS) Key Strengths (3)
Keeps $36 of every $100 in revenue after operating costs
Revenue surging 81.30% year-over-year
72.63% of shares held by major funds and institutions
Supporting Valuation Data
Codexis Inc (CDXS) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.07x sales
Fairly priced relative to book value
Supporting Valuation Data
Codexis Inc (CDXS) Detailed Analysis Report
Overall Assessment
This company scores 45/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth, Institutional Own.. Profitability is solid with Operating Margin at 35.90%. Growth metrics are encouraging with Revenue Growth at 81.30%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Profit Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (2.07), Price/Book (2.88) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -74.90%, Profit Margin at -62.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -74.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 81.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CDXS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CDXS's Price-to-Sales ratio of 2.07x trades at a deep discount to its historical average of 10.69x (11th percentile). The current valuation is 96% below its historical high of 47.9x set in Nov 2021, and 105% above its historical low of 1.01x in Oct 2023. Over the past 12 months, the PS ratio has compressed from ~4.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Codexis Inc (CDXS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Codexis Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 70M with 81% growth year-over-year. The company is currently unprofitable, posting a -62.5% profit margin.
Key Findings
Revenue growing at 81% YoY, reaching 70M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 20M in free cash flow and 20M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -62.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Codexis Inc maintain 81%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.50, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Codexis Inc.
Bottom Line
Codexis Inc is a high-conviction growth story with revenue accelerating at 81% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -62.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Codexis Inc(CDXS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.